RBM39 Promotes Base Excision Repair to Facilitate the Progression of HCC by Stabilising OGG1 mRNA
Cell Proliferation · 2025
DOI: 10.1111/cpr.70059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Proliferation, 2025. Verfasst von Hongda An und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Graduate School…. Hauptthemen laut MEDLINE: DNA Glycosylases, RNA-Binding Proteins, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Clinical Research Special Project of Anhui Provincial Department of Science and Technology, Research Program of Anhui Provincial Department of Education.
Abstract (Originalsprache)
Targeting base excision repair (BER) has been an attractive strategy in cancer therapeutics. RNA‐binding motif protein 39 (RBM39) modulates the alternative splicing of numerous genes involved in cancer occurrence and progression. However, whether and how RBM39 regulates BER in hepatocellular carcinoma (HCC) remain unclear. Here, we found that under oxidative stress, RBM39 degradation or knockdown decreased BER efficiency in HCC cells using a well‐designed BER reporter. Further assays showed that RBM39 promoted HCC cell proliferation, migration, and invasion, enhancing cell survival and inhibiting apoptosis. Mechanistically, RBM39 interacted with the mRNA of the essential glycosidase 8‐oxoguanine‐DNA glycosylase 1 (OGG1), thereby stabilising OGG1 mRNA. This in turn increases OGG1 expression and promotes BER efficiency in HCC. Moreover, data suggested that RBM39 degradation, combined with oxidative damage, could be more effective for HCC treatment than monotherapy, both in vitro and in xenograft mice models. Overall, we demonstrated that RBM39 regulated OGG1 stabilisation and improved BER efficiency, suggesting that combining the RBM39 degradant indisulam with the oxidising agent KBrO 3 could be an emerging strategy for HCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Graduate School of Peking Union Medical College, Nanjing, China.
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- MOE Innovation Center for Basic Research in Tumor Immunotherapy, Hefei, China.
- Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy, Hefei, China.
ORCID-Profile: Zhu Xu
Förderung
- National Natural Science Foundation of China
- Clinical Research Special Project of Anhui Provincial Department of Science and Technology
- Research Program of Anhui Provincial Department of Education
Zitieren
APA
An, H., Xia, A., Liu, S., Luo, D., Geng, L., Li, B., Sun, B., & Xu, Z. (2025). RBM39 Promotes Base Excision Repair to Facilitate the Progression of HCC by Stabilising OGG1 mRNA. Cell Proliferation. https://doi.org/10.1111/cpr.70059
Vancouver
An H, Xia A, Liu S, Luo D, Geng L, Li B, et al. RBM39 Promotes Base Excision Repair to Facilitate the Progression of HCC by Stabilising OGG1 mRNA. Cell Proliferation. 2025. doi:10.1111/cpr.70059
BibTeX
@article{An2025,
author = {An, Hongda and Xia, Anliang and Liu, Siyuan and Luo, Dongjun and Geng, Longpo and Li, Binghua and Sun, Beicheng and Xu, Zhu},
title = {RBM39 Promotes Base Excision Repair to Facilitate the Progression of HCC by Stabilising OGG1 mRNA},
journal = {Cell Proliferation},
year = {2025},
doi = {10.1111/cpr.70059}
}
EUVIMED